| P2093 | author name string | Sharon L Aukerman | |
| | Yuhong Ning | |
| | Kyle J MacBeth | |
| | Michelle Williams | |
| | Carla Heise | |
| | Helen Brady | |
| | Normand Richard | |
| | Paul W Hollenbach | |
| | Aaron N Nguyen | |
| | Leslie Krushel | |
| P2860 | cites work | Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study | Q24563021 |
| | Decitabine in the treatment of myelodysplastic syndromes | Q24641906 |
| | Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study | Q28301602 |
| | 5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal | Q28384242 |
| | Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. | Q34128471 |
| | Biological effects of 5-azacytidine in eukaryotes | Q34202821 |
| | Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia | Q34659942 |
| | Epigenetic therapy of cancer: past, present and future | Q36399557 |
| | Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines | Q37066258 |
| | DNA methyltransferase inhibitors: class effect or unique agents? | Q37132879 |
| | Azacitidine for the treatment of myelodysplastic syndrome | Q37546018 |
| | Biochemistry of azacitidine: a review. | Q38179013 |
| | The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells | Q39887368 |
| | Azacytidine causes complex DNA methylation responses in myeloid leukemia | Q39940031 |
| | The effect of azacitidine on interleukin-6 signaling and nuclear factor-kappaB activation and its in vitro and in vivo activity against multiple myeloma | Q39987415 |
| | p21(WAF1/CIP1) induction by 5-azacytosine nucleosides requires DNA damage. | Q40020060 |
| | DNA methylation inhibitor 5-Aza-2'-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B. | Q40054309 |
| | 5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells. | Q40118609 |
| | Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines. | Q40309778 |
| | 5-Aza-2'-deoxycytidine induces p21WAF expression by demethylation of p73 leading to p53-independent apoptosis in myeloid leukemia. | Q40479015 |
| | Decitabine induces cell cycle arrest at the G1 phase via p21(WAF1) and the G2/M phase via the p38 MAP kinase pathway | Q44512459 |
| | Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes | Q46438891 |
| | Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation fo | Q48693524 |
| | Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). | Q53547181 |
| | Reversal of p15/INK4b hypermethylation in AML1/ETO-positive and -negative myeloid leukemia cell lines. | Q53592250 |
| | "Pleiotypic response". | Q53605113 |
| | Induction of apoptosis by 5-azacytidine: drug concentration-dependent differences in cell cycle specificity. | Q54167678 |
| | Cell cycle effects and cellular pharmacology of 5-AZA-2?-deoxycytidine | Q54485278 |
| | Immunosuppressive effects of methylglyoxal-bis(guanylhydrazone) on mouse bone marrow and spleen cells and their antagonism by spermidine | Q67016496 |
| | The mechanism of inhibition of protein synthesis by 5-azacytidine in HeLa cells | Q70004129 |
| | Characterization of polyribosomes and maturation of ribosomal RNA in hepatoma cells treated with 5-azacytidine | Q70024413 |
| | Cytotoxicity and mode of action of 5-azacytidine on L1210 leukemia | Q71611069 |
| | Comparison of the antileukemic activity of 5-AZA-2'-deoxycytidine, 1-beta-D-arabinofuranosylcytosine and 5-azacytidine against L1210 leukemia | Q72378355 |
| | Mechanism of 5-azacytidine-induced transfer RNA cytosine-5-methyltransferase deficiency | Q72611418 |
| | The effect of 5-azadeoxycytidine on cell growth and DNA methylation | Q72672747 |
| | The cell cycle related differences in susceptibility of HL-60 cells to apoptosis induced by various antitumor agents | Q72800599 |
| | Effect of cytarabine and decitabine in combination in human leukemic cell lines | Q80624812 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | leukemia | Q29496 |
| | acute myeloid leukemia | Q264118 |
| P304 | page(s) | e9001 | |
| P577 | publication date | 2010-02-02 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines | |
| P478 | volume | 5 | |